Analgesics, Non-Narcotic
City: Hueytown
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Hueytown
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Huntsville
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Huntsville
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Huntsville
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

Digestive System Diseases
City: Birmingham
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Huntsville
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Mobile
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Arizona

Analgesics, Non-Narcotic
City: Greensboro
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Peoria
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Peoria
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Tuscon
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

Arthritis
City: Tucson
Summary: A study evaluating the efficacy and safety of TDS-943 (topical diclofenac spray) compared to oral celecoxib and placebo in subjects with osteoarthritis of the knee.

Cancer Pain
City: Litchfield Park
Summary: A study investigating whether RN624 (alone and in combination with oxycodone) is safe and effective in treating pain due to cancer that has spread to bone.

Digestive System Diseases
City: Peoria
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Tucson
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Arkansas

Analgesics, Non-Narcotic
City: Sherwood
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Sherwood
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

Digestive System Diseases
City: Sherwood
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Nervous System Diseases
City: Little Rock
Summary: A study testing the safety and effectiveness of 2 different does of an investigational drug compared to placebo in volunteers diagnosed with Diabetes (Type 1 or 2) experiencing painful neuropathy for at least 6 months.

California

Analgesics, Non-Narcotic
City: Anaheim
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Anaheim
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Anaheim
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Bakersfield
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Bakersfield
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Carmichael
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Cypruss
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Cypruss
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Garden Grove
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Garden Grove
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: San Diego
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: San Diego
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: San Diego
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Torrance
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Torrance
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Torrance
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

Analgesics, Opioid
City: Fountain Valley
Summary: A research study evaluating an investigational treatment, injected daily, compared to placebo (inactive substance), for Opioid-Induced Constipation (OIC) in men and women with chronic, non-cancer related pain.

City: Los Angeles
Summary: A research study evaluating an investigational treatment, injected daily, compared to placebo (inactive substance), for Opioid-Induced Constipation (OIC) in men and women with chronic, non-cancer related pain.

City: San Diego
Summary: research study evaluating an investigational treatment, injected daily, compared to placebo (inactive substance), for Opioid-Induced Constipation (OIC) in men and women with chronic, non-cancer related pain.

Digestive System Diseases
City: Beverly Hills
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Encinitas
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Foothill Ranch
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Garden Grove
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Mission Vejo
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: San Diego
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Westlake Village
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Colorado

Analgesics, Non-Narcotic
City: Springs
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Springs
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

Digestive System Diseases
City: Castle Rock
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Connecticut

Analgesics, Non-Narcotic
City: Torrington
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Torrington
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

Nervous System Diseases
City: Pawcatuck
Summary: A research study to evaluate an investigational drug for treating pain caused by nerve damage as a result of diabetes.

Florida

Analgesics, Non-Narcotic
City: Beach
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Clearwater
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Clearwater
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Daytona Beach
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Daytona Beach
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Daytona Beach
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Jacksonville
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Jacksonville
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Jupiter
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Jupiter
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Largo
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Largo
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Miami
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Miami
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Miami
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Ocoee
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Ocoee
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Ocoee
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Pembroke Pines
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Pembroke Pines
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Port Orange
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Port Orange
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Port Orange
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: South Miami
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Tampa
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Tampa
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Tampa
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Zephyrhills
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Zephyrhills
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

Analgesics, Opioid
City: Temple Terrace
Summary: A study comparing the level of self-reported pain in hospice patients started on subcutaneous infusions of morphine and hydromorphone (Dialudid) over the initial 8 hours of opioid infusion with and without the preceded co-injection of Hylenex.

Arthritis
City: Clearwater
Summary: A research study of 3 approved medications commonly used to treat pain due to osteoarthritis (OA) or rheumatiod arthritis (RA) in people who also have or are at high risk for heart disease.

City: Clearwater
Summary: A research study evaluating the safety and effectiveness of three different dose regimens of an investigational medication in patients with rheumatoid arthritis.

City: Daytona Beach
Summary: A research study of an investigational medication for the treatment of pain associated with rheumatoid arthritis.

Back Pain
City: Weston
Summary: A study to evaluate the effectiveness of orthopedic spinal supports in the treatment of low back pain.

Digestive System Diseases
City: Boca Raton
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Jupiter
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Miami
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Ocala
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Port Orange
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Tampa
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Georgia

Analgesics, Non-Narcotic
City: Macon
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Macon
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

Digestive System Diseases
City: Atlanta
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Marietta
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Woodstock
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Idaho

Analgesics, Non-Narcotic
City: Hayden Lake
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Hayden Lake
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

Digestive System Diseases
City: Idaho Falls
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Illinois

Analgesics, Non-Narcotic
City: Moline
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Moline
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Rockford
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Rockford
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

Digestive System Diseases
City: Peoria
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Rockford
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Indiana

Digestive System Diseases
City: Elkhart
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Evansville
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Headache Disorders
City: Evansville
Summary: A study assessing the safety of Staccato Prochlorperazine on cardiac repolarization (QTc interval duration) at 2 dose levels compared to placebo in healthy volunteers.

Kansas

Analgesics, Non-Narcotic
City: Prarie Village
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Prarie Village
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Wichita
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Wichita
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

Digestive System Diseases
City: Kansas City
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Wichita
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Kentucky

Nervous System Diseases
City: Paducah
Summary: A study of the safety and efficacy of two dosages of bicifadine SR in adult outpatients with chronic neuropathic pain associated with diabetic peripheral neuropathy.

Louisiana

Analgesics, Non-Narcotic
City: New Liberia
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: New Liberia
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: New Liberia
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Shreveport
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Shreveport
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Shreveport
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

Digestive System Diseases
City: Shreveport
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Maryland

Analgesics, Non-Narcotic
City: Baltimore
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Baltimore
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Baltimore
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Hollywood
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Hollywood
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Laurel
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Laurel
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

Cancer Pain
City: Baltimore
Summary: A research study assessing whether acupuncture helps relieve mucositis pain in patients with leukemia who are undergoing chemotherapy.

Digestive System Diseases
City: Chevy Chase
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Laurel
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Massachusetts

Digestive System Diseases
City: Boston
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Nervous System Diseases
City: Bellingham
Summary: A research study to evaluate an investigational drug for treating pain caused by nerve damage as a result of diabetes.

City: Boston
Summary: A research study evaluating an investigational drug for treating pain caused by nerve damage as a result of diabetes.

Michigan

Analgesics, Non-Narcotic
City: Saginaw
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Saginaw
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

Digestive System Diseases
City: Paw Paw
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Minnesota

Analgesics, Non-Narcotic
City: Chaska
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

Mississippi

Digestive System Diseases
City: Jackson
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Missouri

Digestive System Diseases
City: Mexico City
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Nebraska

Analgesics, Non-Narcotic
City: Omaha
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Omaha
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

Nevada

Digestive System Diseases
City: Henderson
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

New Jersey

Arthritis
City: Haddon Heights
Summary: A research study evaluating the effectiveness of an investigational medication on controlling the signs and symptoms of rheumatoid arthritis in individuals already taking methotrexate.

Back Pain
City: Haddon Heights
Summary: A clinical research study assessing the effectiveness of an investigational pain medication on chronic low back pain.

New York

Digestive System Diseases
City: Brooklyn
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Nervous System Diseases
City: New York
Summary: A research study comparing the effectiveness and safety of an investigational drug compared with duloxetine (an approved medication for the treatment of diabetic neuropathy) and placebo (a pill that does not contain any drug) in reducing pain in patients with painful diabetic neuropathy.

North Carolina

Analgesics, Non-Narcotic
City: Boone
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Boone
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: College
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: College
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Greensboro
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Harrisburg
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Harrisburg
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Harrisburg
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: High Point
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: High Point
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: High Point
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Raleigh
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Raleigh
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Raleigh
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Wilmington
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

Digestive System Diseases
City: Chapel Hill
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: High Point
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Raleigh
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Winston-Salem
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Sleep
City: Durham
Summary: A study to determine how best to manage the sleep problems of people with Chronic Fatigue Syndrome. The study will explore how improvements in sleep affect other Chronic Fatigue symptoms including pain, fatigue, and mood as well as a person's sense of general well-being.

Ohio

Analgesics, Non-Narcotic
City: Canton
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Canton
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Canton
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a documented history of an ulcer related serious upper gastrointestinal event such as bleeding, perforation or obstruction

City: Carlisle
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Columbus
Summary: A 12-month, open-label, US multicenter study to provide long-term safety data for an integrated tablet formulation (PN 400) consisting of esomeprazole (PPI- proton pump inhibitor) and naproxen (NSAID - non-steroidal anti-inflammatory drug) in subjects at risk for developing NSAID-associated upper gastrointestinal ulcers

City: Columbus
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

City: Perrysburg
Summary: A study to evaluate the incidence of gastric ulcers following administration of an integrated tablet formulation consisting of esomeprazole (proton pump inhibitor) and naproxen (non-steroidal anti-inflammatory drug) or naproxen in subjects with medical conditions expected to require daily NSAID therapy for at least 6 months and a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years

Cancer Pain
City: Middletown
Summary: A study investigating whether RN624 (alone and in combination with oxycodone) is safe and effective in treating pain due to cancer that has spread to bone.

Digestive System Diseases
City: Cincinnati
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Cleveland
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

City: Dayton
Summary: A study evaluating the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c.

Headache Disorders
City: Cincinnati
Summary: A clinical research study of an investigational medication for Migraines.

Oklahoma

Analgesics, Non-Narcotic
City: